Tumor Biology

, Volume 35, Issue 10, pp 9549–9556 | Cite as

Expression profile of CYP1A1 and CYP1B1 enzymes in endometrial tumors

  • Ioannis Spyrou
  • Stavros Sifakis
  • Achilles Ploumidis
  • Alexandros E. Papalampros
  • Evangellos Felekouras
  • Aristidis M. Tsatsakis
  • Demetrios A. Spandidos
  • Vasilis P. Androutsopoulos
Research Article

Abstract

The cytochrome P450 CYP1A1 and CYP1B1 enzymes are phase I extrahepatic enzymes involved in the activation of pro-carcinogenic compounds to carcinogenic metabolites. Although differential overexpression of CYP1A1 and CYP1B1 has been documented at the messenger RNA (mRNA) and protein level, studies that have examined CYP1 expression by enzyme activity assays are limited. In the current study, the expression of CYP1A1 and CYP1B1 was investigated in a panel of human tumors of endometrial origin by quantitative reverse transcriptase PCR (qRT-PCR), Western blotting, and enzyme activity assays. The data revealed that approximately 36 % (5/14) and 43 % (6/14) of the endometrial tumors overexpressed CYP1A1 and CYP1B1 mRNA, whereas in 57 % of the endometrial tumors, CYP1 mRNA levels were downregulated. The mean mRNA levels of CYP1B1 and CYP1A1 in endometrial tumors did not show a significant difference compared to normal tissues (p > 0.05). Western blotting confirmed the qRT-PCR results and CYP1A1 and CYP1B1 proteins were shown to be downregulated in 7/14 (50 %) of the tumors and overexpressed in 4/14 (29 %) of the tumors. As regards to enzyme activity, 21 % (3/14) of the endometrial samples revealed elevated CYP1 activity levels across the tumor counterparts. Overall, the data suggest a putative downregulation of CYP1A1 and CYP1B1 expression in endometrial tumors, whereas overexpression of active CYP1 enzymes in 21 % of the tumors highlights the potential use of the latter enzymes as chemotherapeutic targets in endometrial cancer.

Keywords

CYP1A1 CYP1B1 Cancer Metabolism Tumor expression 

Notes

Acknowledgments

This study was supported by the charitable organization Reliable Cancer Therapies (RCT) (Verbier, Switzerland). We thank Dr Athanasios Alegakis for valuable help toward the statistical analysis of the results. We are grateful to Professor Economou at the Institute of Molecular Biology and Biotechnology-Foundation of Research and Technology, for allowing us to use the TLX Beckman ultracentrifuge.

Conflict of interest

None

References

  1. 1.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMedGoogle Scholar
  2. 2.
    Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92.CrossRefPubMedGoogle Scholar
  3. 3.
    Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. 2004;95:1–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Schwarz D, Kisselev P, Ericksen SS, Szklarz GD, Chernogolov A, Honeck H, et al. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R), 18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol. 2004;67:1445–57.CrossRefPubMedGoogle Scholar
  5. 5.
    Rodriguez M, Potter DA. CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res. 2013;11:780–92.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kasai S, Ishigaki T, Takumi R, Kamimura T, Kikuchi H. Beta-catenin signaling induces CYP1A1 expression by disrupting adherens junctions in Caco-2 human colon carcinoma cells. Biochim Biophys Acta. 1830;2013:2509–16.Google Scholar
  7. 7.
    Braeuning A, Kohle C, Buchmann A, Schwarz M. Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway. Toxicol Sci. 2011;122:16–25.CrossRefPubMedGoogle Scholar
  8. 8.
    Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, et al. Tumor specific expression of Cytochrome P450 CYP1B1. Cancer Res. 1997;57:3026–31.PubMedGoogle Scholar
  9. 9.
    Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. 2005;65:3726–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Cheung YL, Kerr AC, McFadyen MCE, Melvin WT, Murray GI. Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumors. Cancer Lett. 1999;139:199–205.CrossRefPubMedGoogle Scholar
  11. 11.
    Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis. 1998;19:291–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Bruno RD, Njar VC. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem. 2007;15:5047–60.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Patterson LH, Murray GI. Tumor cytochrome P450 and drug activation. Curr Pharm Des. 2002;8:1335–47.CrossRefPubMedGoogle Scholar
  14. 14.
    Androutsopoulos VP, Spyrou I, Ploumidis A, Papalampros AE, Kyriakakis M, Delakas D, et al. Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PLoS One. 2013;8:e82487.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci. 1996;93:3294–6.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Androutsopoulos VP, Spandidos DA. The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and p53/p21 upregulation. J Nutr Biochem. 2013;24:496–504.CrossRefPubMedGoogle Scholar
  17. 17.
    Saini S, Hinata H, Majid S, Dahiya R. Functional significance of cytochrome P450 CYP1B1 in endometrial carcinogenesis. Cancer Res. 2009;69:7038–45.CrossRefPubMedGoogle Scholar
  18. 18.
    Hevir N, Sinkovec J, Rizner TL. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: Lower levels of CYP1B1 and increased expression of S-COMT. Mol Cell Endocrinol. 2011;331:158–67.CrossRefPubMedGoogle Scholar
  19. 19.
    Pradhan S, Nagashri MN, Gopinath KS, Kumar A. Expression profiling of CYP1B1 in oral squamous cell carcinoma: counterintuitive downregulation in tumors. PLoS One. 2011;6:e27914.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab. 2008;9:129–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Liehr JC, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT. 4-hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci. 1995;92:9220–4.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    McFadyen MCE, Melvin WT, Murray GI. Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br J Cancer. 2004;91:966–71.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fichtner I, Monks A, Hose C, Stevens MF, Bradshaw TD. The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models. Breast Cancer Res Treat. 2004;87:97–107.CrossRefPubMedGoogle Scholar
  24. 24.
    Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, et al. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther. 2013;12:27–37.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Ioannis Spyrou
    • 1
  • Stavros Sifakis
    • 2
  • Achilles Ploumidis
    • 3
  • Alexandros E. Papalampros
    • 1
  • Evangellos Felekouras
    • 1
  • Aristidis M. Tsatsakis
    • 4
  • Demetrios A. Spandidos
    • 5
  • Vasilis P. Androutsopoulos
    • 4
    • 5
  1. 1.First Department of Surgery, Laiko Hospital, Medical SchoolUniversity of AthensAthensGreece
  2. 2.Department of Obstetrics and Gynecology, General Peripheral Hospital of Heraklion, Medical SchoolUniversity of CreteVoutesGreece
  3. 3.Department of UrologyAsklipeio VoulasAthensGreece
  4. 4.Laboratory of Toxicology, Department of Morphology, Medical SchoolUniversity of CreteVoutesGreece
  5. 5.Laboratory of Clinical Virology, Department of Laboratory Medicine, Medical SchoolUniversity of CreteVoutesGreece

Personalised recommendations